专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明授权

US5656625A Nitrogen-containing cyclohetero cycloheteroaminoaryl derivatives for CNS disorders 失效
标题翻译：用于CNS疾病的含氮环杂环芳基氨基芳基衍生物
公开(公告)号：US5656625A
公开(公告)日：1997-08-12
申请号：US442867
申请日：1995-05-17
申请人： Wayne Bowen , Brian R. de Costa , Celia Dominguez , Xiao-Shu He , Kenner C. Rice
发明人： Wayne Bowen , Brian R. de Costa , Celia Dominguez , Xiao-Shu He , Kenner C. Rice
IPC分类号： C07D207/14 , C07D211/56 , C07D223/12 , C07D409/06 , C07D403/04 , A61K31/55 , C07D413/04 , C07D417/04
CPC分类号： C07D409/06 , C07D207/14 , C07D211/56 , C07D223/12
摘要： Certain nitrogen-containing cyclohetero cycloalkylaminoaryl compounds are described for treatment of CNS disorders such as cerebral ischemia, psychoses and convulsions. Compounds of particular interest are of the formula: ##STR1## wherein each of R.sup.1, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 is independently selected from hydrido, lower alkyl, benzyl, and haloloweralkyl;wherein each of R.sup.2, R.sup.3 and R.sup.8 through R.sup.11 is independently selected from hydrido, hydroxy, loweralkyl, benzyl, phenoxy, benzyloxy and haloloweralkyl; wherein n is an integer of from four to six; wherein m is an integer of from two to four; wherein A is selected from phenyl, naphthyl, benzothienyl, benzofuranyl and thienyl; wherein any of the foregoing A groups can be further substituted with one or more substituents independently selected from hydrido, hydroxy, loweralkyl, loweralkoxy, halo, haloloweralkyl, amino, monoloweralkylamino and diloweralkylamino; or a pharmaceutically acceptable salt thereof.
摘要翻译：描述某些含氮环杂环烷基氨基芳基化合物用于治疗中枢神经系统疾病如脑缺血，精神病和抽搐。特别感兴趣的化合物具有下式：其中R 1，R 4，R 5，R 6和R 7各自独立地选自氢，低级烷基，苄基和卤代低级烷基; 其中R2，R3和R8至R11各自独立地选自氢，羟基，低级烷基，苄基，苯氧基，苄氧基和卤代低级烷基; 其中n为4-6的整数; 其中m是2至4的整数; 其中A选自苯基，萘基，苯并噻吩基，苯并呋喃基和噻吩基; 其中前述A基团中的任一个可以进一步被一个或多个独立地选自氢，羟基，低级烷基，低级烷氧基，卤素，卤代低级烷基，氨基，单低级烷基氨基和二低级烷基氨基的取代基取代。或其药学上可接受的盐。

22. 发明申请

US20050065162A1 MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES 失效
标题翻译：梅拉宁浓缩激素受体配体：取代的1-苄氧基-4-芳基哌嗪类似物
公开(公告)号：US20050065162A1
公开(公告)日：2005-03-24
申请号：US10152189
申请日：2002-05-21
申请人： Alan Hutchison , Linda Gustavson , John Peterson , Dario Doller , Timothy Caldwell , Taeyoung Yoon , Wallace Pringle , Yiping Shen , Cheryl Steenstra , Helen Yin , Xiao-shu He
发明人： Alan Hutchison , Linda Gustavson , John Peterson , Dario Doller , Timothy Caldwell , Taeyoung Yoon , Wallace Pringle , Yiping Shen , Cheryl Steenstra , Helen Yin , Xiao-shu He
IPC分类号： G01N33/53 , A61K31/352 , A61K31/451 , A61K31/495 , A61K31/496 , A61K31/4985 , A61K31/506 , A61K31/551 , A61P3/04 , A61P3/10 , A61P9/00 , A61P15/00 , A61P25/00 , A61P43/00 , C07D209/86 , C07D211/44 , C07D211/52 , C07D213/64 , C07D213/74 , C07D215/12 , C07D215/20 , C07D223/04 , C07D239/47 , C07D243/08 , C07D295/08 , C07D295/096 , C07D295/108 , C07D295/18 , C07D311/18 , C07D311/58 , C07D317/58 , C07D401/12 , C07D471/04 , C07D487/04 , C07D487/08 , C07D513/04 , G01N33/566 , C07D43/14
CPC分类号： C07D513/04 , C07D209/86 , C07D211/52 , C07D213/64 , C07D213/74 , C07D215/12 , C07D215/20 , C07D243/08 , C07D295/096 , C07D295/108 , C07D311/18 , C07D317/58 , C07D401/12 , C07D471/04 , C07D487/04 , C07D487/08
摘要： Melanin concentrating hormone receptor ligands (especially 1-benzyl-4-aryl-piperazines, 1-benzyl-4-aryl-piperidines and related compounds), capable of modulating MCH receptor activity, are provided. Such ligands may be used to modulate MCH binding to MCH receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of metabolic, feeding and sexual disorders in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting MCH receptors (e.g., receptor localization studies).
摘要翻译：提供能够调节MCH受体活性的黑色素浓缩激素受体配体（特别是1-苄基-4-芳基哌嗪，1-苄基-4-芳基哌啶和相关化合物）。这样的配体可用于在体内或体外调节MCH与MCH受体的结合，并且特别可用于治疗人，驯养的伴侣动物和家畜中的各种代谢，喂养和性障碍。还提供了用于治疗这种病症的药物组合物和方法，以及使用这些配体检测MCH受体的方法（例如受体定位研究）。

23. 发明授权

US06509366B2 Substituted imidazoles as selective modulators of Bradykinin B2 receptors 失效
标题翻译：取代的咪唑作为缓激肽B2受体的选择性调节剂
公开(公告)号：US06509366B2
公开(公告)日：2003-01-21
申请号：US09764805
申请日：2001-01-17
申请人： Stanislaw Rachwal , Alan Hutchison , Kenneth Shaw , George D. Maynard , Xiao-shu He , Robert DeSimone , Kevin Hodgetts
发明人： Stanislaw Rachwal , Alan Hutchison , Kenneth Shaw , George D. Maynard , Xiao-shu He , Robert DeSimone , Kevin Hodgetts
IPC分类号： A61K314174
CPC分类号： C07D233/64 , C07D233/68 , C07D401/06
摘要： Disclosed are compounds of the formula: or the pharmaceutically acceptable non-toxic salts thereof wherein Y, R1, R2, R3, R4, R5, R6, R7 R7′ are variables defined herein, which compounds are modulators of Bradykinin B2 receptors. These compounds are therefore useful in the diagnosis and treatment of renal diseases, heart failure, hypertension, Meniere's disease, vaginal inflammation and pain, peripheral circulatory disorders, climacteric disturbance, retinochoroidal circulatory disorders, myocardial ischemia, myocardial infarction, postmyocardial infarction syndrome, angina pectoris, restenosis after percutaneous transluminal coronary angioplasty, hepatitis, liver cirrhosis, pancreatitis, ileus, diabetes, diabetic complications, male infertility, glaucoma, pain, asthma, and rhinitis, and for the increase of permeability of the blood-brain barrier or the blood-brain-tumor barrier.
摘要翻译：公开了下式的化合物或其药学上可接受的无毒盐，其中Y，R 1，R 2，R 3，R 4，R 5，R 6，R 7 R 7'是本文定义的变量，该化合物是缓激肽B2受体的调节剂。因此，这些化合物可用于诊断和治疗肾脏疾病，心力衰竭，高血压，梅尼埃病，阴道炎症和疼痛，外周循环障碍，更年期障碍，视网膜循环障碍，心肌缺血，心肌梗死，心肌梗死后综合征，心绞痛经皮腔内冠状动脉血管成形术，肝炎，肝硬化，胰腺炎，肠梗阻，糖尿病，糖尿病并发症，男性不育症，青光眼，疼痛，哮喘和鼻炎的再狭窄，以及增加血脑屏障或血液 - 脑肿瘤屏障。

24. 发明授权

US06441175B1 1-(N'-arylalkylaminoalkyl)aminoisoquinolines: a new class of dopamine receptor subtype 失效
标题翻译： 1-（N'-芳基烷基氨基烷基）氨基异喹啉：新一类多巴胺受体亚型
公开(公告)号：US06441175B1
公开(公告)日：2002-08-27
申请号：US09885847
申请日：2001-06-20
申请人： Xiao-shu He , Brian de Costa , Jan W. F. Wasley
发明人： Xiao-shu He , Brian de Costa , Jan W. F. Wasley
IPC分类号： C07D40112
CPC分类号： C07D401/12 , C07D209/44 , C07D217/22 , C07D403/12
摘要： Disclosed are compounds of the formula or the pharmaceutically acceptable salts thereof wherein the variables R5, R11, R12, R13, R1, R11, Ar, n, m and L are defined herein. These compounds are useful in treating various neuropsychochological disorders including, for example, schizophrenia, dementia, depression, anxiety, Parkinson-like motor disorders and motion disorders related to the use of neuroleptic agents affective disorders such as schizophrenia and depression as well as certain movement disorders such as Parkinsonism. Furthermore, compounds of this invention may be useful in treating the extrapyramidyl side effects associated with the use of conventional neuroleptic agents. The interaction of 1-(N′-(arylalkylaminoalkyl))aminoisoindole derivatives of the invention with dopamine receptor subtypes is described. This interaction results in the pharmacological activities of these compounds.
摘要翻译：公开了下列化合物或其药学上可接受的盐，其中变量R5，R11，R12，R13，R1，R11，Ar，n，m和L在本文中定义。这些化合物可用于治疗各种神经心理障碍，包括例如，精神分裂症，痴呆，抑郁症，焦虑症，类似帕金森综合征的运动障碍以及与使用精神分裂症药物，情感障碍如精神分裂症和抑郁症以及某些运动障碍如帕金森综合征有关的运动障碍。此外，本发明的化合物可用于治疗与常规精神抑制剂的使用相关的外贴剂副作用。描述了本发明的1-（N' - （芳基烷基氨基烷基））氨基异吲哚衍生物与多巴胺受体亚型的相互作用。这种相互作用导致这些化合物的药理活性。

25. 发明授权

US06284759B1 2-piperazinoalkylaminobenzo-azole derivatives: dopamine receptor subtype specific ligands 失效
标题翻译： 2-哌嗪基烷基氨基苯并唑衍生物：多巴胺受体亚型特异性配体
公开(公告)号：US06284759B1
公开(公告)日：2001-09-04
申请号：US09408644
申请日：1999-09-30
申请人： Xiao Shu He
发明人： Xiao Shu He
IPC分类号： A61K31496
CPC分类号： C07D263/58 , C07D235/30 , C07D277/82 , C07D413/12 , C07D417/12
摘要： Disclosed are compounds of the formula: or pharmaceutically acceptable salts thereof, wherein: A is (un)substituted alkylene; R1 and R2 are the same or different and represent hydrogen, halogen, alkyl, alkoxy, alkylthio, hydroxy, (un)substitutedamino, cyano, nitro, sulfonamide, trifluoromethyl or trifluoromethoxy; R3, R4, R5, R6, and R8 are independently hydrogen or alkyl; and X is sulfur, oxygen or NR7 where R8 is defined herein; m is an integer chosen from 0, 1 or 2; and Ar is an aryl or heteroaryl group as further defined herein, which compounds are useful for the treatment and/or prevention of neuropsychological disorders including, but not limited to, schizophrenia, mania, dementia, depression, anxiety, compulsive behavior, substance abuse, Parkinson-like motor disorders and motion disorders related to the use of neuroleptic agents.
摘要翻译：公开了下式的化合物或其药学上可接受的盐，其中：A是（未）取代的亚烷基; R 1和R 2相同或不同，代表氢，卤素，烷基，烷氧基，烷硫基，羟基，（取代的）取代的氨基，氰基，硝基，磺酰胺，三氟甲基或三氟甲氧基; R3，R4，R5，R6和R8独立地是氢或烷基; 并且X是硫，氧或NR 7，其中R 8在本文中定义; m是选自0,1或2的整数; 并且Ar是本文进一步定义的芳基或杂芳基，所述化合物可用于治疗和/或预防神经心理障碍，包括但不限于精神分裂症，躁狂症，痴呆，抑郁症，焦虑症，强迫行为，药物滥用，帕金森病类运动障碍和与使用精神安定药有关的运动障碍。

26. 发明授权

US06252077B1 1-(N′-(arylalkylaminoalkyl) aminoisoquinolines; a new class of dopamine receptor subtype specific ligands 失效
标题翻译： 1-（N' - （芳基烷基氨基烷基）氨基异喹啉;一类新的多巴胺受体亚型特异性配体
公开(公告)号：US06252077B1
公开(公告)日：2001-06-26
申请号：US09470594
申请日：1999-12-22
申请人： Xiao-shu He , Brian de Costa , Jan W. F. Wasley
发明人： Xiao-shu He , Brian de Costa , Jan W. F. Wasley
IPC分类号： C07D20940
CPC分类号： C07D401/12 , C07D209/44 , C07D217/22 , C07D403/12
摘要： Disclosed are compounds of the formula or the pharmaceutically acceptable salts thereof wherein the 6-membered A ring may be optionally substituted with up to four groups independently selected from halogen, hydroxy, lower alkyl, or lower alkoxy; Ar represents optionally substituted aryl or heteroaryl Z represents carbon or nitrogen provided that where Z is carbon, R11 represents hydrogen, halogen, hydroxy, lower alkyl, or lower alkoxy, or phenyl optionally substituted with one or two groups selected from hydrogen, halogen, hydroxy, lower alkyl, or lower alkoxy; and where Z is nitrogen, R11 represents an electron pair; R5 is hydrogen or lower alkyl; m represents an integer; n is 0, or an integer; R12 and R13 independently represent lower alkyl; CR′R″ represent a methylene group optionally substituted with lower alkyl; and k is 1, which compounds are useful in treating various neuropsychological disorders including, for example, schizophrenia, dementia, depression, anxiety, Parkinson-like motor disorders and motion disorders related to the use of neuroleptic agents.
摘要翻译：公开的是式的化合物或其药学上可接受的盐，其中6元环可任选被至多四个独立地选自卤素，羟基，低级烷基或低级烷氧基的基团取代; Ar表示任选取代的芳基或杂芳基Z表示碳或氮，其中Z是碳，R 11表示氢，卤素，羟基，低级烷基或低级烷氧基，或任选被一个或两个选自氢，卤素，羟基，低级烷基或低级烷氧基的基团取代的苯基; 并且其中Z是氮，R11表示电子对; R5是氢或低级烷基; m表示整数; n是0或整数; R12和R13独立地表示低级烷基; CR'R“表示任选的亚甲基被低级烷基取代; andk是1，哪些化合物可用于治疗各种神经心理障碍，包括例如精神分裂症，痴呆，抑郁症，焦虑症，帕金森样运动障碍和与使用神经安定药相关的运动障碍。

27. 发明授权

US5856318A Nitrogen-containing cyclohetero cyclo-heteroaminoaryl derivatives for CNS disorders 失效
标题翻译：用于CNS疾病的含氮环杂环芳基芳基衍生物
公开(公告)号：US5856318A
公开(公告)日：1999-01-05
申请号：US910302
申请日：1997-08-11
申请人： Wayne Bowen , Brian R. de Costa , Celia Dominguez , Xiao-Shu He , Kenner C. Rice
发明人： Wayne Bowen , Brian R. de Costa , Celia Dominguez , Xiao-Shu He , Kenner C. Rice
IPC分类号： C07D207/14 , C07D211/56 , C07D223/12 , C07D409/06 , A61K31/33 , A61K31/55 , C07D295/00 , C07D405/00
CPC分类号： C07D409/06 , C07D207/14 , C07D211/56 , C07D223/12
摘要： Certain nitrogen-containing cyclohetero cycloalkylaminoaryl compounds are described for treatment of CNS disorders such as cerebral ischemia, psychoses and convulsions. Compounds of particular interest are of the formula: ##STR1## wherein each of R.sup.1, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 is independently selected from hydrido, lower alkyl, benzyl, and haloloweralkyl;wherein each of R.sup.2, R.sup.3 and R.sup.8 through R.sup.11 is independently selected from hydrido, hydroxy, loweralkyl, benzyl, phenoxy, benzyloxy and haloloweralkyl; wherein n is an integer of from four to six; wherein m is an integer of from two to four; wherein A is selected from phenyl, naphthyl, benzothienyl, benzofuranyl and thienyl; wherein any of the foregoing A groups can be further substituted with one or more substituents independently selected from hydrido, hydroxy, loweralkyl, loweralkoxy, halo, haloloweralkyl, amino, monoloweralkylamino and diloweralkylamino; or a pharmaceutically acceptable salt thereof.
摘要翻译：描述某些含氮环杂环烷基氨基芳基化合物用于治疗中枢神经系统疾病如脑缺血，精神病和抽搐。特别感兴趣的化合物具有下式：其中R 1，R 4，R 5，R 6和R 7各自独立地选自氢，低级烷基，苄基和卤代低级烷基; 其中R2，R3和R8至R11各自独立地选自氢，羟基，低级烷基，苄基，苯氧基，苄氧基和卤代低级烷基; 其中n为4-6的整数; 其中m是2至4的整数; 其中A选自苯基，萘基，苯并噻吩基，苯并呋喃基和噻吩基; 其中前述A基团中的任一个可以进一步被一个或多个独立地选自氢，羟基，低级烷基，低级烷氧基，卤素，卤代低级烷基，氨基，单低级烷基氨基和二低级烷基氨基的取代基取代。或其药学上可接受的盐。

28. 发明授权

US5679679A Aralkyl diazabicycloalkane derivatives for CNS disorders 失效
标题翻译：用于CNS病症的芳烷基二氮杂双环烷烃衍生物
公开(公告)号：US5679679A
公开(公告)日：1997-10-21
申请号：US348654
申请日：1994-12-02
申请人： Wayne Bowen , Brian R. de Costa , Celia Dominguez , Xiao-Shu He , Kenner C. Rice
发明人： Wayne Bowen , Brian R. de Costa , Celia Dominguez , Xiao-Shu He , Kenner C. Rice
IPC分类号： A61K31/495 , C07D471/04 , C07D487/04 , C07D31/495 , C07D31/55
CPC分类号： C07D471/04 , A61K31/495 , C07D487/04
摘要： Certain aralkyl diazabicyloalkyl compounds are described for treatment of CNS disorders such as cerebral ischemia, psychoses and convulsions. Compounds of particular interest are of the formula: ##STR1## wherein: each of R.sup.1, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 is independently selected from the group consisting of hydrido, loweralkyl, benzyl and haloloweralkyl; each of R.sup.2, R.sup.3, and R.sup.8 through R.sup.11 is independently selected from the group consisting of hydrido, hydroxy, loweralkyl, benzyl, phenoxy, benzyloxy and haloloweralkyl; n is an integer of from three to four; m is an integer of two; A is selected from the group consisting of phenyl, naphthyl, benzothienyl, benzofuranyl and thienyl and wherein any of the foregoing A groups can be further substituted with one or more substituents independently selected from the group consisting of hydrido, hydroxy, loweralkyl, loweralkoxy, halo, haloloweralkyl, amino, monoloweralkylamino and diloweralkylamino; or a pharmaceutically acceptable salt thereof.
摘要翻译：描述了某些芳烷基二氮杂双环烷基化合物用于治疗中枢神经系统疾病如脑缺血，精神病和抽搐。特别感兴趣的化合物具有下式：其中：R 1，R 4，R 5，R 6和R 7各自独立地选自氢，低级烷基，苄基和卤代低级烷基; R 2，R 3和R 8至R 11各自独立地选自氢，羟基，低级烷基，苄基，苯氧基，苄氧基和卤代低级烷基; n是3至4的整数; m是2的整数; A选自苯基，萘基，苯并噻吩基，苯并呋喃基和噻吩基，其中任何前述A基团可以进一步被一个或多个独立地选自羟基，羟基，低级烷基，低级烷氧基，卤代，卤代低级烷基，氨基，单低级烷基氨基和二低级烷基氨基; 或其药学上可接受的盐。

29. 发明授权

US5679673A Aralkyl bridged diazabicycloalkane derivatives for CNS disorders 失效
标题翻译：用于CNS病症的芳烷基桥连二氮杂双环烷烃衍生物
公开(公告)号：US5679673A
公开(公告)日：1997-10-21
申请号：US344304
申请日：1994-11-21
申请人： Wayne Bowen , Brian R. de Costa , Celia Dominguez , Xiao-Shu He , Kenner C. Rice
发明人： Wayne Bowen , Brian R. de Costa , Celia Dominguez , Xiao-Shu He , Kenner C. Rice
IPC分类号： C07D453/02 , C07D487/08 , A61K31/55 , C07D471/08
CPC分类号： C07D487/08 , C07D453/02
摘要： Certain aralkyl diazabicycloalkyl compounds are described for treatment of CNS disorders such as cerebral ischemia, psychoses and convulsions. Compounds of particular interest are of the formula: ##STR1## wherein each of R, R.sup.1, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 is independently selected from hydrido, lower-alkyl, benzyl, and haloloweralkyl; wherein each of R.sup.2, R.sup.3 and R.sup.10 through R.sup.13 is independently selected from hydrido, hydroxy, loweralkyl, benzyl, phenoxy, benzyloxy and haloloweralkyl; wherein each of R.sup.8 and R.sup.9 is selected from hydrido, loweralkyl, benzyl and haloloweralkyl; wherein m is an integer of from two to four; wherein A is selected from phenyl, naphthyl, benzothiophenyl, benzofuranyl and thienyl; wherein any of the foregoing A groups can be further substituted with one or more substituents independently selected from hydrido, hydroxy, loweralkyl, loweralkoxy, halo, haloloweralkyl, amino, monoloweralkylamino and diloweralkylamino; or a pharmaceutically acceptable salt thereof.
摘要翻译：描述了某些芳烷基二氮杂双环烷基化合物用于治疗中枢神经系统疾病如脑缺血，精神病和抽搐。特别感兴趣的化合物具有下式：其中R，R 1，R 4，R 5，R 6和R 7各自独立地选自氢，低级烷基，苄基和卤代低级烷基; 其中R2，R3和R10至R13各自独立地选自氢，羟基，低级烷基，苄基，苯氧基，苄氧基和卤代低级烷基; 其中R8和R9各自选自氢，低级烷基，苄基和卤代低级烷基; 其中m是2至4的整数; 其中A选自苯基，萘基，苯并噻吩基，苯并呋喃基和噻吩基; 其中前述A基团中的任一个可以进一步被一个或多个独立地选自氢，羟基，低级烷基，低级烷氧基，卤素，卤代低级烷基，氨基，单低级烷基氨基和二低级烷基氨基的取代基取代。或其药学上可接受的盐。

30. 发明授权

US5656632A 1-(N'-(arylalkylaminoalkyl)) aminoisoindoles; dopamine receptor subtype specific ligands 失效
标题翻译： 1-（N' - （芳基烷基氨基烷基））氨基异吲哚; 多巴胺受体亚型特异性配体
公开(公告)号：US5656632A
公开(公告)日：1997-08-12
申请号：US463037
申请日：1995-06-05
申请人： Xiao-shu He , Brian de Costa , Jan W. F. Wasley
发明人： Xiao-shu He , Brian de Costa , Jan W. F. Wasley
IPC分类号： C07D209/44 , C07D401/12 , C07D403/12 , A61K31/495 , A61K31/50 , C07D217/02 , C07D401/00
CPC分类号： C07D401/12 , C07D209/44 , C07D403/12
摘要： Disclosed are compounds of the formula ##STR1## or the pharmaceutically acceptable salts thereof wherein the 6-membered A ring may be optionally substituted with up to four groups independently selected from halogen, hydroxy, lower alkyl, or lower alkoxy;Ar represents optionally substituted aryl or heteroarylZ represents carbon or nitrogen provided thatwhere Z is carbon, R.sub.11 represents hydrogen, halogen, hydroxy, lower alkyl, or lower alkoxy, or phenyl optionally substituted with one or two groups selected from hydrogen, halogen, hydroxy, lower alkyl, or lower alkoxy; andwhere Z is nitrogen, R.sub.11 represents an electron pair;R.sub.5 is hydrogen or lower alkyl;L and m represent integers;n is 0, or an integer;R.sub.12 and R.sub.13 independently represent lower alkyl; or together may together form an optionally substituted 5-11 membered ring with the nitrogen atoms to which they are bonded;CR'R" represents a methylene group optionally substituted with lower alkyl; andk is an integer of from 1 to 3,which compounds are useful in treating various neuropsychochological disorders including, for example, schizophrenia, dementia, depression, anxiety, Parkinson-like motor disorders and motion disorders related to the use of neuroleptic agents.
摘要翻译：公开了式IMA的化合物或其药学上可接受的盐，其中6元环可任选被至多四个独立地选自卤素，羟基，低级烷基或低级烷氧基的基团取代; Ar表示任选取代的芳基或杂芳基Z表示碳或氮，条件是其中Z为碳，R11表示氢，卤素，羟基，低级烷基或低级烷氧基，或任选被一个或两个选自氢，卤素，羟基，低级烷基或低级烷氧基; 并且其中Z是氮，R11表示电子对; R5是氢或低级烷基; L和m表示整数; n为0，或整数; R 12和R 13独立地表示低级烷基; 或一起可以一起形成与它们所键合的氮原子的任选取代的5-11元环; CR'R“表示任选被低级烷基取代的亚甲基; k为1〜3的整数，该化合物可用于治疗各种神经精神障碍，包括精神分裂症，痴呆，抑郁症，焦虑症，帕金森样运动障碍以及与使用精神抑制药有关的运动障碍。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式